These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1509712)

  • 1. [Clinical manifestations of insulin resistance. The hormonal-metabolic syndrome X (5H), its prevalence and impact on cardiovascular morbidity and mortality. I].
    Hrnciar J; Hrnciarová M; Jakubíková K; Okapcová J
    Vnitr Lek; 1992 May; 38(5):426-37. PubMed ID: 1509712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical manifestations of the insulin resistance syndrome. The hormonal-metabolic syndrome X, the 5H syndrome and their etiopathogenesis].
    Hrnciar J
    Vnitr Lek; 1995 Feb; 41(2):92-8. PubMed ID: 7725646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperinsulinism as a major etiopathogenic link with arterial hypertension, hyperlipoproteinemia and hirsutism. II].
    Hrnciar J; Hrnciarová M; Jakubíková K; Okapcová J
    Vnitr Lek; 1992 May; 38(5):438-47. PubMed ID: 1509713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relation between levels of leptin, insulin and cortisol in persons with the 5H (X) syndrome].
    Hrnciar J; Okapcová J; Lepej J; Gábor D
    Vnitr Lek; 1998 Feb; 44(2):68-75. PubMed ID: 9820079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperinsulinism and the coronary syndrome].
    Hrnciar J
    Vnitr Lek; 1992 Nov; 38(11):1056-65. PubMed ID: 1494868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Insulin resistance and arterial hypertension. Hyperinsulinism as a basic etiopathogenic factor in essential arterial hypertension and associated phenomena].
    Hrnciar J; Hrnciarová M; Jakubíková K; Korónyi S
    Vnitr Lek; 1992 Sep; 38(9):868-78. PubMed ID: 1481385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How should we implement the basic principles of treatment of type 2 diabetes mellitus from the aspect of the hormono-metabolic syndrome X (5H)?].
    Hrnciar J; Jakubíková K; Okapcová J
    Vnitr Lek; 1992 Aug; 38(8):729-37. PubMed ID: 1455753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The dilemma of syndrome X].
    Hrnciar J
    Vnitr Lek; 1992 Nov; 38(11):1041-4. PubMed ID: 1494865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome].
    Hrnciar J
    Vnitr Lek; 1996 Aug; 42(8):557-60. PubMed ID: 8967027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin resistance and arterial hypertension].
    Hrnciarová M; Hrnciar J; Jakubíková K
    Vnitr Lek; 1995 Feb; 41(2):111-6. PubMed ID: 7725634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The metabolic syndrome, its heredity, methods of detection and clinical significance].
    Válek J; Vlasáková Z
    Vnitr Lek; 1997 Sep; 43(9):566-73. PubMed ID: 9750464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovarian syndrome: the next cardiovascular dilemma in women?
    Srikanthan P; Korenman S; Davis S
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):611-31, x. PubMed ID: 16959589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of certain parameters in the diagnosis and detection of metabolic X syndrome].
    Suba I; Halmos T; Kautzky L
    Orv Hetil; 1997 Sep; 138(38):2407-11. PubMed ID: 9380379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B; Gambineri A; Pasquali R
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk factors are really linked in the metabolic syndrome: this phenomenon suggests clustering rather than coincidence.
    Aizawa Y; Kamimura N; Watanabe H; Aizawa Y; Makiyama Y; Usuda Y; Watanabe T; Kurashina Y
    Int J Cardiol; 2006 May; 109(2):213-8. PubMed ID: 16023231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans.
    Lyoussi B; Ragala MA; Mguil M; Chraibi A; Israili ZH
    Clin Exp Hypertens; 2005 May; 27(4):377-94. PubMed ID: 15921074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico.
    Rabelo Acevedo M; Vick MR
    P R Health Sci J; 2005 Sep; 24(3):203-6. PubMed ID: 16329683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome' in a middle-aged Finnish population.
    Vanhala MJ; Kumpusalo EA; Pitkäjärvi TK; Takala JK
    J Cardiovasc Risk; 1997 Aug; 4(4):291-5. PubMed ID: 9477208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.